HER2-positive

About

Biomarker type: Protein expression

Marker: Human epidermal growth factor receptor 2 (HER2)

Unit: status

Equality: =

Value: Positive

Mappings
View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this biomarker.

Organizations Biomarkers Cancer types Therapies
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Trastuzumab emtansine
FDA (1) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Capecitabine
FDA (1) HC (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Lapatinib
FDA (1) ER positive, HER2-positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Lapatinib, Letrozole
FDA (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Eribulin, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Gemcitabine, Margetuximab
FDA (1) HER2-positive Invasive Breast Carcinoma Margetuximab, Vinorelbine
FDA (1) HER2-positive Invasive Breast Carcinoma Neratinib
FDA (1) HC (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Neratinib
FDA (1) HC (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Cisplatin, Fluorouracil, Pembrolizumab, Trastuzumab
FDA (1) HER2-positive, PD-L1 (CPS) >= 1 Adenocarcinoma of the Gastroesophageal Junction Capecitabine, Oxaliplatin, Pembrolizumab, Trastuzumab
FDA (2) HC (5) HER2-positive Invasive Breast Carcinoma Docetaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (4) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Fluorouracil, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Doxorubicin, Fluorouracil, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Epirubicin, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Epirubicin, Paclitaxel, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Cyclophosphamide, Docetaxel, Doxorubicin, Pertuzumab, Trastuzumab
FDA (2) HC (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Pertuzumab, Trastuzumab
FDA (1) HC (2) HER2-positive Invasive Breast Carcinoma Trastuzumab
FDA (1) HER2-positive Gastrointestinal Stromal Tumor Trastuzumab
FDA (1) HC (2) HER2-positive Invasive Breast Carcinoma Trastuzumab deruxtecan
FDA (1) HC (1) HER2-positive Adenocarcinoma of the Gastroesophageal Junction Trastuzumab deruxtecan
FDA (1) HC (1) HER2-positive Any solid tumor Trastuzumab deruxtecan
FDA (1) HC (1) HER2-positive Invasive Breast Carcinoma Capecitabine, Trastuzumab, Tucatinib
FDA (1) HER2-positive Intraductal Papillary Neoplasm of the Bile Duct Zanidatamab
FDA (1) HER2-positive Intracholecystic Papillary Neoplasm Zanidatamab
FDA (1) HER2-positive Cholangiocarcinoma Zanidatamab
HC (1) HER2-positive Invasive Breast Carcinoma Carboplatin, Docetaxel, Trastuzumab
HC (1) ER positive, HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
HC (1) ER positive, HER2-positive Invasive Breast Carcinoma Neratinib
HC (1) HER2-positive, PR positive Invasive Breast Carcinoma Neratinib
HC (2) HER2-positive Invasive Breast Carcinoma Carboplatin, Paclitaxel, Pertuzumab, Trastuzumab
HC (2) HER2-positive Invasive Breast Carcinoma Paclitaxel, Pertuzumab, Trastuzumab
HC (2) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab, Vinorelbine
HC (1) HER2-positive Invasive Breast Carcinoma Docetaxel, Paclitaxel, Trastuzumab
FDA (1) HER2-positive, Wild type KRAS, Wild type NRAS Colorectal Adenocarcinoma Trastuzumab, Tucatinib
FDA (1) HER2-positive Invasive Breast Carcinoma Pertuzumab, Trastuzumab deruxtecan